Tannock G A, Gillett S M, Gillett R S, Barry R D, Hensley M J, Herd R, Reid A L, Saunders N A
Faculty of Medicine, University of Newcastle, Royal Newcastle Hospital, New South Wales, Australia.
Epidemiol Infect. 1988 Dec;101(3):611-21. doi: 10.1017/s0950268800029484.
The efficacy of interferon A (rIFN-alpha 2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18-65 years) self-administered 1.5, 3.0 and 6.0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%). No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms.
1985年澳大利亚冬季，在一项基于社区的双盲安慰剂对照研究中，评估了大肠杆菌衍生的干扰素A（重组干扰素α2A）预防急性上呼吸道感染的疗效。412名健康志愿者（190名男性和222名女性，年龄在18至65岁之间）组成的试验人群每天自行鼻内给予1.5、3.0和6.0百万单位（MU）的干扰素A或安慰剂，持续28天。研究期间恰逢H3N2甲型流感爆发（107份急性标本中有35份检测到），以及大量呼吸道合胞病毒和腺病毒感染。仅从三份标本中分离出鼻病毒。在许多情况下，受试者在研究期间有实验室和临床证据表明患有不止一种呼吸道感染。107份急性标本中有54份检测到病毒（49%）。在经实验室证实的病毒感染（病毒分离和/或抗体反应）发生率方面，各治疗组之间未发现统计学上的显著差异。对报告症状的分析表明，高剂量干扰素使用时，带血黏液和鼻塞出现得更频繁。使用干扰素A改善症状似乎没有临床益处。
